Incyte
Lilly’s RA drug baricitinib meets Phase III goals
March 31, 2016Research and Development Eli Lilly, Incyte, rheumatoid arthritis
Eli Lilly and Incyte have announced the publication of detailed Phase III trial results from a study of their biologic …
Incyte to stop Jakafi pancreatic, colorectal cancer drug trials
February 11, 2016Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer
Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …
Lilly awaits FDA review of new arthritis treatment
January 20, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis
Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …
AstraZeneca and MedImmune in oncology research deals
January 12, 2016Manufacturing and Production, Research and Development AstraZeneca, Incyte, MedImmune, Moderna Therapeutics
AstraZeneca and its biologics arm MedImmune are launching new agreements with partner companies, to develop new targets for cancer, and …
Merck and Incyte to initiate Keytruda, epacadostat combo trial
October 15, 2015Research and Development Incyte, Merck, R&D, melanoma, phase III, skin cancer
Merck and biopharma firm Incyte are to expand their clinical collaboration to include a Phase III study evaluating the combination …
MedImmune signs Incyte oncology deal
May 15, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Incyte, MedImmune, oncology
MedImmune, the global biologics R&D arm of AstraZeneca, is to put one of its oncology immunotherapies into development in combination …
Incyte names former Novartis president as its chief executive
January 14, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Incyte, Novartis, hoppenot
Biopharma firm Incyte has announced that the former president of Novartis Oncology has been named as its president and chief …
Novartis’ myelofibrosis treatment approved in Europe
August 28, 2012Sales and Marketing Incyte, Jakavi, Novartis, Orphan Drugs, myelofibrosis
Novartis’ Jakavi, a new treatment for patients with myelofibrosis has been approved in Europe. The drug was co-developed with Incyte, …
Novartis plans Q2 filing for blood cancer drug
March 17, 2011Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib
Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …
Incyte’s Novartis cancer drug deal could be worth $1bn
December 1, 2009Research and Development Incyte, Novartis
Novartis has paid Incyte Corporation $150 million up front for the rights to two oral investigational hematology-oncology therapies.The first is …
Latest content
Five Facts about cardiovascular disease
